CALGARY, AB, Feb. 28, 2022 /CNW/ - Universal Ibogaine Inc.
(TSXV:IBO ) (OTCQB: IBOGF) ("UI" or the "Company") a
life sciences company with a mission to transform the world of
addiction treatment through medicalized ibogaine and a state of the
art ongoing care program, is pleased to announce that its common
shares have been approved for trading on the OTCQB Venture Market
(the "OTCQB") under the ticker "IBOGF". UI will
continue to trade in Canada on the
TSX Venture Exchange under its current ticker symbol IBO. The
UI common shares trading in the United
States have also been approved for DTC eligibility.
The OTCQB Venture Market is for early stage and developing U.S.
and international companies, which are current in their reporting
and undergo an annual verification and management certification
process. Investors can find Real-Time quotes and market
information for the Company on www.otcmarkets.com
Universal Ibogaine CEO Nick
Karos stated: "Accessing the vast USA market of retail and institutional
investors through the OTC platform will provide our current
and future shareholders enhanced liquidity and expanded global
exposure for the Company, which will assist with our future
financing and growth plans. We look forward to working with
the OTC Markets Group, as the USA
is a key future addiction treatment market for us, with over
100,000 lives lost to opioid overdose last year
alone."
OTC Markets Group Inc. operates the OTCQX® Best
Market, the OTCQB® Venture Market and the Pink® Open Market for
11,000 U.S. and global securities. Through OTC Link® ATS and OTC
Link ECN, it connects a diverse network of broker-dealers that
provide liquidity and execution services. It enables investors to
easily trade through the broker of their choice and empowers
companies to improve the quality of information available for
investors.
About Universal Ibogaine Inc.
UI is a life sciences company, with a mission to demonstrate the
safety and efficacy of its ibogaine based drug detox protocol
through a planned Canadian Clinical Trial, and ultimately to
utilize that protocol around the globe through future licensing
agreements. UI is concurrently developing a state of the art
holistic addiction treatment protocol at its Kelburn Clinic that,
which when paired with the planned ibogaine detox protocol, is
intended to revolutionize the way we treat addiction and
drastically improve the lives of individuals and families affected
by addiction.
NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES
PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX
VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR
ACCURACY OF THIS RELEASE.
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING
STATEMENTS
This news release may contain forward-looking statements and
information. Forward-looking information is frequently
characterized by words such as "plans", "expect", "project",
"intend", "will", "believe", "anticipate", "estimate", "scheduled",
"potential", or other similar words, or statements that certain
events or conditions "may", "should" or "could" occur. The
forward-looking statements and information are based on certain key
expectations and assumptions made by UI. Although UI
believes that the expectations and assumptions on which the
forward-looking statements are based are reasonable, undue
reliance should not be placed on the forward-looking statements
because UI can give no assurance that they will prove to be
correct.
Since forward-looking statements address future events and
conditions, by their very nature they involve inherent risks and
uncertainties. Actual results could differ materially from those
currently anticipated due to a number of factors and risks, which
include, but are not limited to, risks that required regulatory
approvals are not obtained. The reader is cautioned that
assumptions used in the preparation of such information, although
considered reasonable by UI at the time of preparation, may prove
to be incorrect and readers are cautioned not to place undue
reliance on forward-looking information, which speaks only to
conditions as of the date hereof. UI does not undertake any
obligation to release publicly any revisions to forward-looking
information contained herein to reflect events or circumstances
that occur after the date hereof or to reflect the occurrence of
unanticipated events, except as may be required under applicable
securities laws.
Related
Links
https://universalibogaine.com
SOURCE Universal Ibogaine Inc.
